Related Experiment Video

Updated: Mar 16, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K

Pharmacological treatments of cardiovascular diseases: Evidence from real-life studies

Francesco Salvo1, Julien Bezin1, Pauline Bosco-Levy2

  • 1University of Bordeaux, UMR1219, F-33000 Bordeaux, France; INSERM, UMR1219, Bordeaux Population Health Research Center, Pharmacoepidemiology Team, Bordeaux, France; CHU Bordeaux, Bordeaux, France.

Pharmacological Research
|August 10, 2016
PubMed

Insights

This review examines real-world drug use and effectiveness for chronic cardiovascular diseases, including acute coronary syndrome, heart failure, and atrial fibrillation, to identify knowledge gaps and future research directions.

Area of Science:

  • Cardiology and Pharmacology
  • Public Health and Epidemiology

Background:

  • Chronic cardiovascular diseases remain leading causes of global mortality.
  • Significant advancements in managing acute coronary syndrome have reduced acute mortality.
  • New pharmacological options for heart failure and atrial fibrillation present management challenges.

Purpose of the Study:

  • To provide updated information on real-world drug utilization and effectiveness in cardiovascular disease management.
  • To identify potential knowledge gaps in current treatment strategies.
  • To suggest future directions for pharmaco-epidemiological research in cardiovascular pharmacotherapy.

Main Methods:

  • Literature review focused on recent advancements and real-world data.
  • Assessment of drug use patterns and treatment effectiveness.
  • Analysis of challenges in managing chronic cardiovascular conditions.

Main Results:

  • Evolving management strategies for acute coronary syndrome and secondary prevention.
  • Increased complexity in pharmacotherapy for heart failure and non-valvular atrial fibrillation.
  • Highlighting the need for updated evidence on drug effectiveness in real-world settings.

Conclusions:

  • Continued evolution in cardiovascular disease management necessitates updated evidence on drug use and effectiveness.
  • Addressing knowledge gaps is crucial for optimizing patient outcomes.
  • Pharmaco-epidemiology offers a valuable framework for future research in this domain.

Keywords:
AnticoagulantsAtrial fibrillationEvidence based cardiovascular medicationsHeart failurePharmacoepidemiologySecondary cardiovascular prevention

More Related Videos

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.1K
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

2.2K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
564
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.5K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
363
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
584
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
470
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K